Introduction
============

Noncoding RNAs (ncRNAs) are RNAs that lack protein-coding functions.[@b1-ott-11-2453] On the basis of their characteristics, ncRNAs can be divided into several classes, including lncRNAs, miRNAs, small interfering RNAs, small nuclear RNAs, and ribosomal RNAs.[@b1-ott-11-2453] miRNAs are a class of small ncRNAs with important regulatory roles, \~22 nt in length.[@b2-ott-11-2453] They can posttranscriptionally regulate gene expression through binding to miRNA response elements (MREs) on their target transcripts.[@b3-ott-11-2453],[@b4-ott-11-2453] A single miRNA can regulate up to hundreds of target genes, and each gene may also be modulated by multiple miRNAs.[@b5-ott-11-2453],[@b6-ott-11-2453] Aberrantly expressed miRNAs are associated with many diseases including cancer.[@b7-ott-11-2453]--[@b10-ott-11-2453]

In 2011, Salmena et al presented a competing endogenous RNA (ceRNA) hypothesis, which proposed a new "language" among different types of RNA transcripts.[@b11-ott-11-2453] The hypothesis postulates that RNA molecules can communicate with each other through shared MREs. MRNAs, lncRNAs, and other RNA transcripts could act as endogenous miRNA sponges to inhibit miRNA function, thereby impact the multiple targets of multiple miRNAs.[@b11-ott-11-2453] RNA transcripts sharing one or more MREs can actively regulate their respective expression levels by competing for a limited pool of miRNAs. This ceRNA crosstalk forms a large-scale regulatory network across the transcriptome, including protein-coding and noncoding RNAs.[@b11-ott-11-2453] LncRNAs, a class of ncRNAs \>200 nt in length, are suggested to participate in various biological processes (BPs) by regulating gene expression at transcriptional, post-transcriptional, and epigenetic levels.[@b12-ott-11-2453]--[@b14-ott-11-2453] Recent studies have provided emerging support for the ceRNA activity of lncRNAs involved in the progression of various types of cancer.[@b15-ott-11-2453]--[@b18-ott-11-2453] LncRNA-associated ceRNA networks have been constructed and analyzed in lung squamous cell carcinoma, papillary renal cell carcinoma, hepatocellular carcinoma, and gastric cancer.[@b19-ott-11-2453]--[@b22-ott-11-2453] However, there have been few integrated analyses of lncRNA-associated ceRNA networks in colorectal cancer (CRC).

In the present study, we conducted a comprehensive analysis of the mRNA, lncRNA, and miRNA expression profiles in CRC and constructed a CRC-specific lncRNA-associated ceRNA network using a large cohort from The Cancer Genome Atlas (TCGA). To the best of our knowledge, our study is the first to establish an lncRNA-associated ceRNA network in CRC using a combined dataset of colon adenocarcinoma and rectum adenocarcinoma from TCGA. The results are expected to help to further elucidate the lncRNA--miRNA--mRNA crosstalk in CRC and generate insight into the molecular mechanisms involved in the tumorigenesis and progression of CRC.

Patients and methods
====================

Selection of CRC patients
-------------------------

The mRNA, lncRNA, and miRNA expression quantification files and the corresponding clinical information for CRC patients were obtained from TCGA (<https://cancergenome.nih.gov/>). The inclusion criteria were as follows: 1) patients with complete clinical information including age, gender, pathological stage, TNM stage, survival status, and survival time; 2) patients with complete RNA-Seq data of mRNAs and lncRNAs, and complete miRNA-Seq data; 3) patients with a follow-up survival time of ≤2,000 days. After filtering with the inclusion criteria, a total of 539 CRC patients and 11 normal controls were finally enrolled in the study. The clinicopathological characteristics of the CRC patients are summarized in [Table 1](#t1-ott-11-2453){ref-type="table"}.

Expression profile analysis of mRNAs, lncRNAs, and miRNAs in CRC and normal tissues
-----------------------------------------------------------------------------------

The differentially expressed mRNAs, lncRNAs, and miRNAs (hereafter referred to as "DEmRNAs", "DEln-cRNAs", and "DEmiRNAs", respectively) in CRC and normal tissues were screened out individually using the edgeR package in the R language with the threshold of \|log~2~fold change (log~2~FC)\| \>2 and false discovery rate (FDR) \<0.01.[@b23-ott-11-2453] Hierarchical clustering analysis was then performed using the pheatmap package in R (Version 1.0.8) to evaluate the specificity of the differentially expressed RNAs.[@b24-ott-11-2453]

Construction of the ceRNA network
---------------------------------

The interactions between DElncRNAs and DEmiRNAs were predicted by miRcode.[@b25-ott-11-2453] The mRNAs targeted by the DEmiRNAs were retrieved according to TargetScan, miRTarBase, and miRDB.[@b26-ott-11-2453]--[@b28-ott-11-2453] Only mRNAs recognized by all three databases were considered as candidate mRNAs and intersected with the DEmRNAs to screen out the DEmRNAs targeted by the DEmiRNAs. Then, the lncRNA--miRNA--mRNA ceRNA network was constructed based on the DEmiRNA--DElncRNA and DEmiRNA--DEmRNA interactions and visualized using the Cytoscape software.[@b29-ott-11-2453] A flowchart of the lncRNA--miRNA--mRNA ceRNA network analysis is displayed in [Figure 1](#f1-ott-11-2453){ref-type="fig"}. Linear regression analysis was performed to evaluate the correlation between ceRNA expression levels.

Survival analysis
-----------------

For each of the DEmRNAs, DElncRNAs, and DEmiRNAs in the ceRNA network, the CRC patients were classified into either a high expression group or a low expression group using the median expression value of the specific RNA as the cutoff value. The differences in patients' survival time between the high expression group and the low expression group were then evaluated by Kaplan--Meier survival curve and log-rank test analysis to find the mRNAs, lncRNAs, and miRNAs that were significantly associated with the survival of CRC patients. *P*\<0.05 was set as the threshold for statistical significance.

The associations between key lncRNAs and clinical features
----------------------------------------------------------

Based on the bioinformatics analysis and the ceRNA network, key lncRNAs were screened out. The lncRNAs were then analyzed to determine whether they were differentially expressed between different clinical feature categories, including gender (male vs female), T stage (T3 + T4 vs Tis + T1 + T2), N stage (N1 + N2 vs N0), M stage (M1 vs M0), and pathological stage (stage III + IV vs stage I + II). Differentially expressed key lncRNAs with \|log~2~FC\|\>1 and FDR\<0.05 were considered significantly associated with the relevant clinical feature.

Functional enrichment analysis
------------------------------

Functional enrichment analysis was performed for the DEmRNAs in the ceRNA network to reveal the functional implications of these mRNAs in the tumorigenesis of CRC. Gene Ontology (GO) functional enrichment analysis was conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID, Version 6.8) online tool.[@b30-ott-11-2453] Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was carried out using the KEGG Orthology-Based Annotation System (KOBAS).[@b31-ott-11-2453] *P*\<0.05 was set as the statistical significance threshold criterion for both GO and KEGG enrichment analysis.

Results
=======

Cancer-specific mRNAs, lncRNAs, and miRNAs in CRC
-------------------------------------------------

According to the cutoff threshold, a total of 1,767 DEmRNAs (including 854 upregulated and 913 downregulated) were screened out between CRC tissues and normal tissues. The expressions of 608 DElncRNAs (including 370 upregulated and 238 downregulated) and 283 DEmiRNAs (including 201 upregulated and 82 downregulated) were altered significantly in CRC tissues compared with normal tissues. Unsupervised hierarchical clustering analysis was performed for the top 100 upregulated and top 100 downregulated mRNAs and lncRNAs (owing to the large amount of DEmRNAs and DElncRNAs), respectively, and all the DEmiRNAs. The heatmaps showed that the CRC samples could be clearly distinguished from the normal samples with respect to the expression of these differentially expressed RNAs ([Figure 2A--C](#f2-ott-11-2453){ref-type="fig"}).

DElncRNA--DEmiRNA interactions predicted by miRcode
---------------------------------------------------

The lncRNAs that are targeted by miRNAs were predicted by miRcode. Only interactions between DElncRNAs and DEmiRNAs were selected for ceRNA network construction. As a result, 479 interactions between 67 DElncRNAs (including KCNQ1OT1, ADAMTS9-AS2, and AGAP11) and 32 DEmiRNAs (including hsa-mir-106a, hsa-mir-141, and hsa-mir-143) were identified for further analysis.

Prediction of DEmRNAs targeted by DEmiRNAs
------------------------------------------

The 32 DEmiRNAs recognized in the above step were mapped into TargetScan, miRTarBase, and miRDB databases to search for their target mRNAs. A total of 1,416 mRNAs were found to be targeted by these DEmiRNAs in all three databases. These candidate mRNAs were then intersected with the DEmRNAs, and 52 of the 1,416 mRNAs were identified as the DEmRNAs targeted by the DEmiRNAs. Among the 32 candidate DEmiRNAs, only 25 were found to interact with these 52 DEmRNAs, the remaining seven DEmiRNAs without specific DEmRNA targets were excluded from further analysis. To highlight the ceRNA features of the network, only DEmiRNAs interacting with both DEmRNAs and DElncRNAs were introduced into the ceRNA network. Finally, 25 DEmiRNAs, 52 DEmRNAs, and 64 DElncRNAs were selected for ceRNA network construction.

The ceRNA network in CRC
------------------------

Based on the above data, an lncRNA--miRNA--mRNA ceRNA network consisting of 141 molecules and 450 interactions (382 DEmiRNA--DElncRNA interactions and 68 DEmiRNA--DEmRNA interactions) was constructed. The top 11 DElncRNAs targeted by most DEmiRNAs are shown in [Table 2](#t2-ott-11-2453){ref-type="table"}. All the 64 DElncRNAs in the ceRNA network with their name, Ensembl ID, log~2~FC, and FDR are listed in [Table S1](#SD1-ott-11-2453){ref-type="supplementary-material"}. All the 25 DEmiRNAs with their target DEmRNAs in the ceRNA network are shown in [Table 3](#t3-ott-11-2453){ref-type="table"}. The network was visualized with Cytoscape and is displayed in [Figure 3](#f3-ott-11-2453){ref-type="fig"}. According to the ceRNA network, there is a possibility of indirect interactions between DElncRNAs and DEmRNAs. To confirm our finding, linear regression analysis was performed. The results suggested a good positive correlation between ceRNA expression levels ([Figures 4A--I](#f4-ott-11-2453){ref-type="fig"} and [5A--H](#f5-ott-11-2453){ref-type="fig"}). For example, mediated by hsa-mir-106a, LINC00461 interacted with CADM2, CFL2, and FAM129A while mediated by hsa-mir-424, LINC00461 interacted with TMEM100 and TPM2 ([Figure 4A, E, D, F, and H](#f4-ott-11-2453){ref-type="fig"}). Mediated by hsa-mir-152, LINC00484 interacted with BMP3 and KLF4 while mediated by hsa-mir-141, LINC00484 interacted with PHLPP2 ([Figure 5 A, D, and C](#f5-ott-11-2453){ref-type="fig"}).

Important RNAs associated with the prognosis of CRC patients
------------------------------------------------------------

Kaplan--Meier survival curve and log-rank test analysis were performed for each of the DElncRNAs, DEmiRNAs, and DEmRNAs in the ceRNA network to find the RNAs significantly associated with the survival of CRC patients. According to the results, two DElncRNAs (AP004609.1 and C2orf48), five DEmiRNAs (hsa-mir-96, hsa-mir-144, hsa-mir-145, hsa-mir-193b, and hsa-mir-375), and six DEmRNAs (FAM46C, FJX1, HAND1, SERPINE1, TPM2, and ULBP2) were identified as prognosis-related RNAs (*p*\<0.05, [Figures 6A and B](#f6-ott-11-2453){ref-type="fig"}, [7A--E](#f7-ott-11-2453){ref-type="fig"}, and [8A--F](#f8-ott-11-2453){ref-type="fig"}). Among these, hsa-mir-144, and hsa-mir-375 (DEmiRNA) and FAM46C (DEmRNA) appeared to be protective, as patients with higher expression levels of these RNAs tended to have longer overall survival, compared with those with lower expression levels of these RNAs ([Figures 7B and E](#f7-ott-11-2453){ref-type="fig"}, and [8A](#f8-ott-11-2453){ref-type="fig"}). The remaining two DElncRNAs, three DEmiRNAs, and five DEmRNAs were considered risky, as their high expression was associated with shorter overall survival of CRC patients.

Key lncRNAs relevant to clinical features
-----------------------------------------

The 64 DElncRNAs from the ceRNA network were further analyzed to find their associations with clinical features. The lncRNA expression profiles of CRC patients were compared between different genders, T, N, and M (tumor, node, and metastasis) stages, and pathological stages. Four key DElncR-NAs were found to be significantly differentially expressed in clinical feature comparisons. AC110491.1 was significantly altered between genders (male vs female). H19 and HULC were not only differentially expressed in advanced-stage patients (stage III + IV) compared with earlier-stage patients (stage I + II), but also appeared to be associated with N stage (N1 + N2 vs N0) and M stage (M1 vs M0). As well as H19 and HULC, CLDN10-AS1 was also indicated to be an M stage-associated DElncRNA. The key DElncRNAs relevant to clinical features are summarized in [Table 4](#t4-ott-11-2453){ref-type="table"}.

Functional enrichment analysis
------------------------------

Functional enrichment analysis revealed that a total of 28 GO terms, including 20 BP terms, 4 cellular component terms, and 4 molecular function terms were enriched by the DEmRNAs in the ceRNA network. Some of the GO terms were concerned with regulation of transcription, such as GO:0045892\~negative regulation of transcription, DNA-templated and GO:0001190\~transcriptional activator activity, RNA polymerase II transcription factor binding ([Table 5](#t5-ott-11-2453){ref-type="table"}).

The KEGG pathway enrichment analysis was also performed for the DEmRNAs. Ten KEGG pathways were found to be significantly enriched by the DEmRNAs in the ceRNA network, among which hsa04115: p53 signaling pathway, hsa05206: MicroRNAs in cancer, hsa04310: Wnt signaling pathway, and hsa04390: Hippo signaling pathway were closely associated with the pathogenesis of cancer ([Table 6](#t6-ott-11-2453){ref-type="table"}).

Discussion
==========

CRC is one of the most common malignancies worldwide, ranking the third in men and the second in women.[@b32-ott-11-2453] Despite numerous studies endeavoring to reveal the mechanisms of CRC, the exact pathogenesis has remained to be elucidated. In recent years, a novel hypothesis has been proposed that different RNA transcripts could interact with each other through shared MREs.[@b11-ott-11-2453] This is called "the ceRNA hypothesis" and presents a new pattern of gene expression regulation that could be used to further understand the mechanisms of various diseases including cancer.

In the present study, we identified DElncRNAs, DEmiRNAs, and DEmRNAs between CRC tissues and normal tissues, using a large cohort from the TCGA database. Then, an lncRNA--miRNA--mRNA ceRNA network was constructed, which provided an integrated view of the ceRNA regulatory crosstalk among these CRC-specific RNA transcripts. The DElncRNAs in the ceRNA network were analyzed for their associations with the survival and clinical features of CRC patients. Functional enrichment analysis further revealed the BPs and pathways associated with the DEmRNAs involved in the development of CRC.

Dysregulated lncRNAs have been observed in various cancers, and some of them have been demonstrated to be associated with patient survival.[@b33-ott-11-2453]--[@b36-ott-11-2453] For instance, decreased expression of the lncRNA MLLT4 antisense RNA 1 indicates poor prognosis in gastric cancer patients, whereas overexpression of the lncRNA linc-UBC1 is associated with poor prognosis in CRC.[@b34-ott-11-2453],[@b35-ott-11-2453] In the present study, two DElncRNAs from the ceRNA network, namely AP004609.1 and C2orf48, were found to be significantly associated with the survival of patients with CRC. Both of them could be considered life threatening, as patients with high expression levels of these two lncRNAs tended to have shorter survival times than patients with low expression. Although little is known about the functions of these two DElncRNAs, our results indicate the prognostic potential of the lncRNAs in survival prediction and provide new directions for further investigation of the two lncRNAs involved in CRC.

With respect to the associations between DElncRNAs and clinical features, we found that four DElncRNAs were related to clinical features, including gender, N stage, M stage, and tumor pathological stage. Among the four DElncRNAs, H19, a widely studied lncRNA, has been suggested as an indicator of tumor progression in multiple types of cancers, including CRC.[@b37-ott-11-2453]--[@b40-ott-11-2453] H19 has been reported to indicate poor prognosis and promote tumor growth in CRC.[@b39-ott-11-2453] Overexpression of H19 is associated with decreased overall survival rates in CRC patients, as well as increased viability and migration in colon cancer cells.[@b40-ott-11-2453] In our study, the expression of H19 was significantly upregulated in advanced tumor stages (stages N1/N2, M1, and stage III/IV) compared with earlier tumor stages (stages N0, M0, and stage I/II). The findings of our study were consistent with previous reports and further confirmed the important function of H19 in the progression of CRC.

MiRNAs, the hub elements of the ceRNA network, exhibited key roles in the crosstalk among different RNA transcripts. Mediated by hsa-mir-424, LINC00461 interacted with TMEM100 and TPM2 while LINC00484 interacted with TMEM100 and PHLPP2 in the present CRC-specific ceRNA network. Mediated by hsa-mir-141, LINC00461 interacted with ELAVL4 while LINC00484 interacted with PHLPP2. Both hsa-mir-424 and hsa-mir-141 were demonstrated to be involved in the pathogenesis of CRC.[@b41-ott-11-2453],[@b42-ott-11-2453] We also found five miRNAs to be significantly associated with the prognosis in CRC. High expression of hsa-mir-96, hsa-mir-145, and hsa-mir-193b indicated an unfavorable clinical outcome, while upregulation of hsa-mir-144 and hsa-mir-375 suggested longer survival times of patients with CRC. All the key DEmiRNAs show promising potential as biomarkers for survival prediction in CRC.

MRNAs comprise another important part of the ceRNA network, through being directly targeted by miRNAs or having indirect interactions with lncRNAs mediated by miRNAs. Similar to lncRNAs and miRNAs, some mRNAs were also found to be associated with the survival of CRC patients, such as the protective mRNA FAM46C, and the risky mRNAs including FJX1, HAND1, SERPINE1, TPM2, and ULBP2. Furthermore, functional enrichment analysis revealed that DEmRNAs were enriched in some BPs and pathways related to transcription regulation and cancer, such as negative regulation of transcription, the p53 signaling pathway, and the Wnt signaling pathway.[@b43-ott-11-2453],[@b44-ott-11-2453] The close correlation between the enriched pathways and the ceRNA network demonstrates the credibility of our results.

Conclusion
==========

The present study identified CRC-specific lncRNAs, miRNAs, and mRNAs using a large cohort from the TCGA database. We successfully constructed an lncRNA-associated ceRNA network, which provided insight into the newly proposed crosstalk among different types of RNA transcripts. Key lncRNAs were analyzed to determine significant associations with overall survival and clinical features of CRC patients. Hub miRNAs also showed promising potential as prognostic biomarkers in CRC. Our study provides better understanding of the ceRNA regulatory mechanism and helps to elucidate the pathogenesis involved in the tumorigenesis and progression of CRC.

Supplementary material
======================

###### 

All the 64 DElncRNAs in the ceRNA network

  DElncRNAs       Ensembl ID        Log~2~FC   FDR         DElncRNAs    Ensembl ID        Log~2~FC   FDR
  --------------- ----------------- ---------- ----------- ------------ ----------------- ---------- -----------
  ABCA9-AS1       ENSG00000231749   3.9864     1.50E--03   ERVMER61-1   ENSG00000230426   6.2730     4.00E--03
  AC007384.1      ENSG00000237513   −2.4205    6.92E--14   FAM95B1      ENSG00000223839   −2.0743    4.64E--06
  AC009065.1      ENSG00000259780   2.4120     7.23E--03   FRMD6-AS2    ENSG00000258537   −3.1025    7.09E--09
  AC009093.1      ENSG00000259807   3.0580     8.28E--05   GAS6-AS1     ENSG00000233695   3.5499     1.09E--07
  AC009336.1      ENSG00000272729   −2.0597    6.03E--06   H19          ENSG00000130600   4.1017     5.86E--04
  AC010336.2      ENSG00000260500   −2.7897    2.57E--14   HCG23        ENSG00000228962   −2.5508    3.36E--13
  AC012640.1      ENSG00000248968   2.4459     2.90E--04   HULC         ENSG00000251164   6.8799     6.67E--03
  AC016745.1      ENSG00000234997   3.6141     4.61E--03   JAZF1-AS1    ENSG00000234336   −2.6263    2.05E--13
  AC020907.1      ENSG00000179066   3.8949     3.35E--03   KCNQ1-AS1    ENSG00000229414   2.53016    6.52E--03
  AC064836.2      ENSG00000272966   2.5934     4.09E--03   KCNQ1OT1     ENSG00000269821   2.0209     1.35E--05
  AC084262.1      ENSG00000260253   3.2217     4.57E--03   LIFR-AS1     ENSG00000244968   −2.3659    2.13E--13
  AC110491.1      ENSG00000261292   −4.8260    3.22E--22   LINC00092    ENSG00000225194   −2.8438    8.99E--30
  ADAMTS9-AS1     ENSG00000241158   −3.9253    2.66E--28   LINC00330    ENSG00000235097   −2.9422    1.32E--07
  ADAMTS9-AS2     ENSG00000241684   −2.8713    5.15E--21   LINC00402    ENSG00000235532   −2.7266    1.25E--09
  AGAP11          ENSG00000271880   −2.1666    1.83E--07   LINC00460    ENSG00000233532   6.2479     1.30E--08
  AL138995.1      ENSG00000277763   −2.4069    1.42E--17   LINC00461    ENSG00000245526   −2.9817    1.73E--13
  AL161431.1      ENSG00000275216   5.7502     7.72E--07   LINC00473    ENSG00000223414   −3.3201    6.64E--17
  AL360004.1      ENSG00000196979   −2.3594    1.39E--06   LINC00484    ENSG00000229694   −3.1173    2.08E--16
  AL512652.1      ENSG00000275485   2.02862    2.74E--04   LINC00488    ENSG00000214381   −3.1742    1.39E--10
  AL513123.1      ENSG00000236347   3.0582     5.80E--05   LINC00507    ENSG00000256193   −4.1785    5.34E--24
  AL590483.1      ENSG00000229960   2.8803     7.85E--06   LMO7-AS1     ENSG00000261105   2.4135     6.21E--05
  AP000553.1      ENSG00000272954   3.3636     2.14E--05   MIR22HG      ENSG00000186594   −2.0251    9.64E--22
  AP002478.1      ENSG00000266401   4.3909     1.13E--04   MYO16-AS1    ENSG00000236242   3.8592     6.26E--03
  AP004609.1      ENSG00000245869   −2.0890    7.59E--05   PCAT1        ENSG00000253438   2.4776     4.83E--07
  C17orf77        ENSG00000182352   4.1557     1.43E--03   POU6F2-AS1   ENSG00000224122   5.8205     4.29E--03
  C20orf166-AS1   ENSG00000174403   −3.4682    8.37E--20   PVT1         ENSG00000249859   2.6328     2.82E--18
  C2orf48         ENSG00000163009   2.2264     3.27E--05   PWRN1        ENSG00000259905   −2.2617    1.55E--04
  C7orf69         ENSG00000136275   3.2131     9.71E--03   RBMS3-AS3    ENSG00000235904   −2.7161    1.60E--13
  CLDN10-AS1      ENSG00000223392   4.5630     6.72E--04   SFTA1P       ENSG00000225383   −2.7508    1.59E--11
  CRNDE           ENSG00000245694   4.4129     1.47E--12   ST7-OT4      ENSG00000214188   2.4463     6.43E--04
  DLX6-AS1        ENSG00000231764   4.3820     1.38E--03   UCA1         ENSG00000214049   3.9110     1.06E--04
  EGOT            ENSG00000235947   2.3163     2.49E--03   WASIR2       ENSG00000231439   2.1913     8.49E--03

**Abbreviations:** FDR, false discovery rate; log~2~FC, log~2~fold change.
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![Flowchart of the lncRNA--miRNA--mRNA ceRNA network analysis.](ott-11-2453Fig1){#f1-ott-11-2453}

###### 

Heatmaps based on the differentially expressed RNAs in CRC and normal tissues.

**Notes:** (**A**) The heatmap with top 100 upregulated and top 100 downregulated mRNAs. (**B**) The heatmap with top 100 upregulated and top 100 downregulated lncRNAs. (**C**) The heatmap with all the DEmiRNAs.

**Abbreviation:** CRC, colorectal cancer.
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![The lncRNA--miRNA--mRNA ceRNA network in CRC.\
**Notes:** Red rounds represent upregulated DEmRNAs and blue rounds represent downregulated DEmRNAs. Red squares represent upregulated DElncRNAs and blue squares represent downregulated DElncRNAs. Green triangles represent upregulated DEmiRNAs and yellow triangles represent downregulated DEmiRNAs.\
**Abbreviation:** CRC, colorectal cancer.](ott-11-2453Fig3){#f3-ott-11-2453}

![Linear regression of ceRNA expression levels for LINC00461.\
**Notes:** LINC00461 vs (**A**) CADM2, (**B**) GRIK3, (**C**) ELAVL4, (**D**) FAM129A, (**E**) CFL2, (**F**) TMEM100, (**G**) NOVA1, (**H**) TPM2, and (**I**) MIXL1. The red line represents the linear model fitted by the dots in each figure, while green lines represent the 95% CI. "Cor" represents the correlation between the expressions of LINC00461 and the specific mRNA.](ott-11-2453Fig4){#f4-ott-11-2453}

![Linear regression of ceRNA expression levels for LINC00484.\
**Notes:** LINC00484 vs (**A**) BMP3, (**B**) UGP2, (**C**) PHLPP2, (**D**) KLF4, (**E**) PBLD, (**F**) EPB41L3, (**G**) TMEM100, and (**H**) SFRP1. The red line represents the linear model fitted by the dots in each figure while green lines represent the 95% CI. "Cor" represents the correlation between the expressions of LINC00484 and the specific mRNA.](ott-11-2453Fig5){#f5-ott-11-2453}

![Kaplan--Meier survival curves for the two DElncRNAs significantly associated with overall survival of CRC patients. **Note:** Kaplan--Meier survival curves for (**A**) AP004609.1 and (**B**) C2orf48.\
**Abbreviation:** CRC, colorectal cancer.](ott-11-2453Fig6){#f6-ott-11-2453}

![Kaplan--Meier survival curves for the five DEmiRNAs significantly associated with overall survival of CRC patients.\
**Note:** Kaplan--Meier survival curves for (**A**) hsa-mir-96, (**B**) hsa-mir-144, (**C**) hsa-mir-145, (**D**) hsa-mir-193b, and (**E**) hsa-mir-375.\
**Abbreviation:** CRC, colorectal cancer.](ott-11-2453Fig7){#f7-ott-11-2453}

![Kaplan--Meier survival curves for the six DEmRNAs significantly associated with overall survival of CRC patients.\
**Note:** Kaplan--Meier survival curves for (**A**) FAM46C, (**B**) FJX1, (**C**) HAND1, (**D**) SERPINE1, (**E**) TPM2, and (**F**) ULBP2.\
**Abbreviation:** CRC, colorectal cancer.](ott-11-2453Fig8){#f8-ott-11-2453}

###### 

Clinicopathological characteristics of 539 CRC patients

  Clinicopathological characteristics   Patients (N=539)   
  ------------------------------------- ------------------ -------
  Age category (years)                                     
   \<65                                 220                40.82
   ≥65                                  319                59.18
  Gender                                                   
   Female                               252                46.75
   Male                                 287                53.25
  Pathological stage                                       
   Stage I                              99                 18.37
   Stage II                             192                35.62
   Stage III                            163                30.24
   Stage IV                             85                 15.77
  Pathologic T                                             
   Tis                                  1                  0.18
   T1                                   18                 3.34
   T2                                   95                 17.63
   T3                                   360                66.79
   T4                                   65                 12.06
  Pathologic N                                             
   N0                                   301                55.85
   N1                                   138                25.60
   N2                                   100                18.55
  Pathologic M                                             
   M0                                   404                74.95
   M1                                   83                 15.40
   Mx                                   52                 9.65
  Survival status                                          
   Alive                                440                81.63
   Dead                                 99                 18.37

**Abbreviation:** CRC, colorectal cancer.

###### 

The top 11 DElncRNAs putatively targeted by most DEmiRNAs in the ceRNA network

  DElncRNAs     DEmiRNAs
  ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  KCNQ1OT1      hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-182, hsa-mir-192, hsa-mir-193b, hsa-mir-206, hsa-mir-217, hsa-mir-223, hsa-mir-301b, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-375, hsa-mir-424, hsa-mir-429, hsa-mir-454, hsa-mir-96, hsa-mir-98
  ADAMTS9-AS2   hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-182, hsa-mir-193b, hsa-mir-223, hsa-mir-301b, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-375, hsa-mir-454, hsa-mir-96, hsa-mir-98
  DLX6-AS1      hsa-mir-106a, hsa-mir-141, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-192, hsa-mir-193b, hsa-mir-206, hsa-mir-223, hsa-mir-338, hsa-mir-372, hsa-mir-424, hsa-mir-429
  AGAP11        hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-182, hsa-mir-193b, hsa-mir-206, hsa-mir-21, hsa-mir-217, hsa-mir-372, hsa-mir-375, hsa-mir-424
  AC010336.2    hsa-mir-106a, hsa-mir-141, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-17, hsa-mir-182, hsa-mir-192, hsa-mir-193b, hsa-mir-338, hsa-mir-372, hsa-mir-429
  LINC00461     hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-192, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-424, hsa-mir-96
  LINC00484     hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-152, hsa-mir-206, hsa-mir-217, hsa-mir-223, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-424, hsa-mir-98
  LIFR-AS1      hsa-mir-106a, hsa-mir-144, hsa-mir-150, hsa-mir-182, hsa-mir-192, hsa-mir-193b, hsa-mir-206, hsa-mir-32, hsa-mir-372, hsa-mir-375, hsa-mir-96
  LINC00330     hsa-mir-106a, hsa-mir-145, hsa-mir-150, hsa-mir-17, hsa-mir-192, hsa-mir-206, hsa-mir-301b, hsa-mir-372, hsa-mir-424, hsa-mir-454, hsa-mir-98
  FAM95B1       hsa-mir-141, hsa-mir-143, hsa-mir-150, hsa-mir-152, hsa-mir-182, hsa-mir-206, hsa-mir-338, hsa-mir-375, hsa-mir-96, hsa-mir-98
  PVT1          hsa-mir-106a, hsa-mir-143, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-21, hsa-mir-217, hsa-mir-372, hsa-mir-424

###### 

The 25 DEmiRNAs with their target DEmRNAs in the ceRNA network

  DEmiRNAs       DEmRNAs
  -------------- ------------------------------------------------------
  hsa-mir-106a   CFL2, FOXQ1, FAM129A, CADM2, FJX1
  hsa-mir-141    ELAVL4, PHLPP2, EPHA7, KIAA1549
  hsa-mir-143    COL1A1, SERPINE1
  hsa-mir-144    KCNQ5, GRIK3
  hsa-mir-145    SERPINE1
  hsa-mir-150    EREG, HILPDA, SLC7A11
  hsa-mir-152    BMP3, NPTX1, KLF4
  hsa-mir-17     FAM46C, FOXQ1, FJX1, CADM2, CYBRD1, FAM129A, CFL2
  hsa-mir-182    CHL1, NPTX1, ULBP2
  hsa-mir-192    GRHL1
  hsa-mir-193b   PLAU
  hsa-mir-206    STC2, SFRP1
  hsa-mir-21     TGFBI
  hsa-mir-217    DACH1
  hsa-mir-223    EPB41L3
  hsa-mir-301b   RBM20, CFL2
  hsa-mir-32     PHLPP2, PBLD, PAX9, UGP2
  hsa-mir-338    NOVA1
  hsa-mir-372    CADM2, TMEM100, SLC7A11, MIXL1
  hsa-mir-375    ELAVL4
  hsa-mir-424    PSAT1, TMEM100, PHLPP2, CBX2, AXIN2, TPM2
  hsa-mir-429    PMAIP1
  hsa-mir-454    CFL2, RBM20
  hsa-mir-96     ALK, TRIB3, SLC1A1
  hsa-mir-98     HAND1, IGF2BP1, PRSS22, RGS16, TRIM71, IGF2BP3, CPA4

###### 

The correlations between DElncRNAs from the ceRNA network and clinical features of CRC patients

  Comparisons                               Upregulated       Downregulated
  ----------------------------------------- ----------------- ---------------
  Gender (male vs female)                                     AC110491.1
  N stage (N1 + N2 vs N0)                   H19               HULC
  M stage (M1 vs M0)                        CLDN10-AS1, H19   HULC
  Pathological stage (III + IV vs I + II)   H19               HULC

**Abbreviation:** CRC, colorectal cancer.

###### 

The top 10 predominant BP terms and all the four CC terms and MF terms in GO functional enrichment analysis

  Categories                                                                                       Terms                                                             Count        *P*-value
  ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------- ------------ ------------
  GO BP                                                                                            GO:0045892\~negative regulation of transcription, DNA-templated   7            3.16 E--03
  GO:0048147\~negative regulation of fibroblast proliferation                                      3                                                                 3.68 E--03   
  GO:0001525\~angiogenesis                                                                         5                                                                 4.02 E--03   
  GO:0043434\~response to peptide hormone                                                          3                                                                 7.30 E--03   
  GO:0071363\~cellular response to growth factor stimulus                                          3                                                                 7.62 E--03   
  GO:0050680\~negative regulation of epithelial cell proliferation                                 3                                                                 0.012        
  GO:0017148\~negative regulation of translation                                                   3                                                                 0.012        
  GO:0001957\~intramembranous ossification                                                         2                                                                 0.017        
  GO:0042035\~regulation of cytokine biosynthetic process                                          2                                                                 0.020        
  GO:0060346\~bone trabecula formation                                                             2                                                                 0.023        
  GO CC                                                                                            GO:0005615\~extracellular space                                   13           1.79 E--04
  GO:0070062\~extracellular exosome                                                                14                                                                0.031        
  GO:0005886\~plasma membrane                                                                      18                                                                0.036        
  GO:0031012\~extracellular matrix                                                                 4                                                                 0.045        
  GO MF                                                                                            GO:0003730\~mRNA 3′-UTR binding                                   3            8.90 E--03
  GO:0045182\~translation regulator activity                                                       2                                                                 0.017        
  GO:0048027\~mRNA 5′-UTR binding                                                                  2                                                                 0.026        
  GO:0001190\~transcriptional activator activity, RNA polymerase II transcription factor binding   2                                                                 0.045        

**Abbreviations:** BP, biological process; CC, cellular component; GO, Gene Ontology; MF, molecular function; UTR, untranslated region.

###### 

KEGG pathways enriched by the DEmRNAs in the ceRNA network

  ID         Terms                                                      *P*-value
  ---------- ---------------------------------------------------------- ------------
  hsa04550   Signaling pathways regulating pluripotency of stem cells   3.51 E--03
  hsa04115   p53 signaling pathway                                      9.51 E--03
  hsa04610   Complement and coagulation cascades                        0.012
  hsa00750   Vitamin B6 metabolism                                      0.014
  hsa04974   Protein digestion and absorption                           0.016
  hsa05206   MicroRNAs in cancer                                        0.019
  hsa04933   AGE-RAGE signaling pathway in diabetic complications       0.020
  hsa04724   Glutamatergic synapse                                      0.024
  hsa04310   Wnt signaling pathway                                      0.036
  hsa04390   Hippo signaling pathway                                    0.041

**Abbreviation:** KEGG, Kyoto Encyclopedia of Genes and Genomes.
